FDA accepts Immune's IND for bertilimumab to treat bullous pemphigoid

The US Food and Drug Administration (FDA) has accepted Immune Pharmaceuticals' investigational new drug (IND) application for its first in class, lead product candidate, bertilimumab, to treat Bullous Pemphigoid (BP).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news